DCM
VRDN icon

Delpha Capital Management’s Viridian Therapeutics VRDN Stock Holding History

Delpha Capital Management’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-24
Closed -$4K – 1187
2017
Q4 		$4K Buy
+24
New +$3.06K ﹤0.01% 1373

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Delpha Capital Management's VRDN Position: Q1 2018 in Review

Delpha Capital Management sold out of Viridian Therapeutics (VRDN) in Q1 2018, closing a stake of 24 shares — an estimated $4K sold.

Delpha Capital Management first reported a position in VRDN in Q4 2017 and held it in 1 quarter. The position peaked at $4K in Q4 2017. 59 funds tracked by Wall St. Rank hold VRDN as of Q1 2018.

  • Delpha Capital Management reported no remaining Viridian Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Delpha Capital Management sold 24 Viridian Therapeutics shares in Q1 2018, an estimated $4K.
  • Delpha Capital Management first reported a position in Viridian Therapeutics in Q4 2017 and held it in 1 quarter.
  • Delpha Capital Management's Viridian Therapeutics position peaked at $4K in Q4 2017.
  • 59 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q1 2018.

Based on Delpha Capital Management's 13F filing for Q1 2018, filed 11 May 2018.